Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.

Autor:	Deipolyi AR; Division of Vascular & Interventional Radiology, Department of Radiology, New York University Medical Center, New York, New York., Oklu R; Section of Interventional Radiology, Department of Radiology, Massachusetts General Hospital and Harvard Medical School., Al-Ansari S; Section of Interventional Radiology, Department of Radiology, Massachusetts General Hospital and Harvard Medical School., Zhu AX; Massachusetts General Hospital Cancer Center, Department of Internal Medicine, Massachusetts General Hospital, 55 Fruit Street, GRB 290, Boston, MA 02114., Goyal L; Massachusetts General Hospital Cancer Center, Department of Internal Medicine, Massachusetts General Hospital, 55 Fruit Street, GRB 290, Boston, MA 02114., Ganguli S; Section of Interventional Radiology, Department of Radiology, Massachusetts General Hospital and Harvard Medical School. Electronic address: sganguli@partners.org.
Jazyk:	angličtina
Zdroj:	Journal of vascular and interventional radiology : JVIR [J Vasc Interv Radiol] 2015 Apr; Vol. 26 (4), pp. 516-22. Date of Electronic Publication: 2015 Feb 18.
DOI:	10.1016/j.jvir.2014.12.020
Abstrakt:	Purpose: To compare the safety and efficacy of using 70-150 μm drug-eluting beads (DEBs) (LC BeadM1; Biocompatibles UK Ltd, Farnham, Surrey, United Kingdom) in addition to 100-300 μm DEBs with 100-300 μm DEBs alone in transarterial chemoembolization for treatment of hepatocellular carcinoma (HCC). Materials and Methods: A cohort of patients with HCC who underwent transarterial chemoembolization with two vials of 100-300 μm DEBs (group 1, 55 procedures among 42 patients, 33 men, average Model for End-Stage Liver Disease score 10 ± 0.6, 67% Child-Pugh A, 33% Child-Pugh B) was retrospectively compared with a cohort of patients who underwent transarterial chemoembolization with one vial of 70-150 μm DEBs followed by one vial of 100-300 μm DEBs (group 2, 51 procedures among 42 patients, 29 men, average Model for End-Stage Liver Disease score 9 ± 0.6, 73% Child-Pugh A, 27% Child-Pugh B) in regard to adverse events and response on 1-month follow-up imaging using modified Response Evaluation Criteria In Solid Tumors criteria. Results: There was no difference in 1-month imaging response (P = .3). Patients in group 2 were readmitted more often within 1 month for hepatobiliary adverse events (group 2, 25%; group 1, 9%; P < .0001), including ascites, gastrointestinal hemorrhage, biliary dilatation, and cholecystitis. Conclusions: Despite similar efficacy based on short-term follow-up imaging, transarterial chemoembolization with smaller DEBs (70-150 μm) followed by larger DEBs (100-300 μm) may cause more hepatobiliary adverse events. (Copyright © 2015 SIR. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu